Efficacy of a plant-produced infectious bronchitis virus-like particle vaccine in specific pathogen-free chickens

Sepotokele, Kamogelo M.; O’Kennedy, Martha M.; Hayes, M.; Wandrag, Daniel B.R.; Smith, Peter; Abolnik, Célia

doi:10.1016/j.psj.2023.102953

Cited by 2 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All procedures involving the care and use of animals were conducted to minimize animal suffering and approved by the Jiangsu Laboratory Animal Welfare and Ethics guidelines of the Jiangsu Administrative Committee for Laboratory Animals (SCXK2018-0009 and SYXK 2021-0027 for chickens and SCXK2017-0007 and SYXK2017-0044 for mice). The mice and chickens used in this study were both euthanized by manual cervical dislocation [13,28]. The SPF broilers and chicken embryos used in this study were purchased from Nanjing Biology Medical Factory, Qian Yuan-hao Biological Co., Ltd., Nanjing, China.…”

Section: Ethical Statementmentioning

confidence: 99%

“…Live attenuated IBV vaccines are effective; however, they carry the risk of reversion to virulence and often involve co-infection with other avian viruses, such as the H9N2 avian influenza virus, resulting in more severe outbreaks [11]. Inactivated IBVs are safe but costly, and elevated levels of protection will be achieved by co-administration with live attenuated vaccines [12,13]. Therefore, there is a need to develop a new vaccine, which not only does not depend on chicken embryos but is also cost-effective and capable of inducing high-efficiency and longlasting immune protection [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salmonella typhimurium Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection

Liu,

Li,

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Infectious bronchitis (IB) is a highly infectious viral disease of chickens which causes significant economic losses in the poultry industry worldwide. An effective vaccine against IB is urgently needed to provide both biosafety and high-efficiency immune protection. In this study, the S1 protein of the infectious bronchitis virus was delivered by a recombinant attenuated Salmonella typhimurium vector to form the vaccine candidate χ11246(pYA4545-S1). S. typhimurium χ11246 carried a sifA− mutation with regulated delayed systems, striking a balance between host safety and immunogenicity. Here, we demonstrated that S1 protein is highly expressed in HD11 cells. Immunization with χ11246(pYA4545-S1) induced the production of antibody and cytokine, leading to an effective immune response against IB. Oral immunization with χ11246(pYA4545-S1) provided 72%, 56%, and 56% protection in the lacrimal gland, trachea, and cloaca against infectious bronchitis virus infection, respectively. Furthermore, it significantly reduced histopathological lesions in chickens. Together, this study provides a new idea for the prevention of IB.

show abstract

Section: Ethical Statementmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Salmonella typhimurium Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection

Liu,

Li,

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development

Mardanova,

Vasyagin,

Ravin

2024

Plants

View full text Add to dashboard Cite

The capsid proteins of many viruses are capable of spontaneous self-assembly into virus-like particles (VLPs), which do not contain the viral genome and are therefore not infectious. VLPs are structurally similar to their parent viruses and are therefore effectively recognized by the immune system and can induce strong humoral and cellular immune responses. The structural features of VLPs make them an attractive platform for the development of potential vaccines and diagnostic tools. Chimeric VLPs can be obtained by attaching foreign peptides to capsid proteins. Chimeric VLPs present multiple copies of the antigen on their surface, thereby increasing the effectiveness of the immune response. Recombinant VLPs can be produced in different expression systems. Plants are promising biofactories for the production of recombinant proteins, including VLPs. The main advantages of plant expression systems are the overall low cost and safety of plant-produced products due to the absence of pathogens common to plants and animals. This review provides an overview of the VLP platform as an approach to developing plant-produced vaccines, focusing on the use of transient expression systems.

show abstract

Efficacy of a plant-produced infectious bronchitis virus-like particle vaccine in specific pathogen-free chickens

Cited by 2 publications

References 30 publications

Salmonella typhimurium Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection

Salmonella typhimurium Vaccine Candidate Delivering Infectious Bronchitis Virus S1 Protein to Induce Protection

Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development

Contact Info

Product

Resources

About